First Patient Injected With Experimental Cancer-Killing Virus in New Clinical Trial
An experimental cancer-killing virus has been administered to a human patient for the first time, with hopes the testing will ultimately reveal evidence of a new means of successfully fighting cancer tumors in people's bodies.
The drug candidate, called CF33-hNIS (aka Vaxinia), is what's called an oncolytic virus, a genetically modified virus designed to selectively infect and kill cancer cells while sparing healthy ones.In the case of CF33-hNIS, the modified pox virus works by entering cells and duplicating itself.…